Core Viewpoint - The company anticipates a decline in revenue and net profit for the first half of 2025, primarily due to inventory reduction and the impact of a fertility subsidy program [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of 9.1-9.3 billion for H1 2025, representing a year-on-year decline of 7.9%-9.9% [1]. - The projected net profit for H1 2025 is estimated to be between 1.0-1.2 billion, reflecting a year-on-year decrease of 36%-47% [1]. - The company plans to allocate no less than 1.0 billion for share buybacks and expects to distribute dividends of at least 2.0 billion in 2025, down from 2.72 billion in the previous year [1][2]. Group 2: Market Outlook - The company forecasts low single-digit growth for full-year revenue, with H2 2025 revenue expected to increase by 10%-15% [2]. - The anticipated completion of inventory adjustments in Q3 2025 is expected to positively impact revenue [2]. - The company plans to launch higher-end products in H2 2025, which may drive revenue improvement [2]. Group 3: Investment Strategy - The company has announced a share buyback plan and a commitment to dividend distribution, enhancing shareholder returns [2][3]. - The long-term outlook remains positive due to expected recovery in newborn population growth and the implementation of fertility subsidies, suggesting a potential industry improvement cycle of 2-3 years [2]. - The company has adjusted its earnings forecasts for 2025-2027, with a target price set at 5.1 HKD and a recommendation downgrade to "recommended" [3].
中国飞鹤(06186.HK)2025年中报预告点评：业绩低于预期 加大分红回购力度